Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general and special meeting of shareholders held on June 1, 2022 (the "Meeting").

The five nominees of management were elected as directors at the Meeting. The voting results for the election of each director nominee are as follows:

At the Meeting, KPMG LLP was appointed as the auditor of the Company for the ensuing year and the directors were authorized to fix the remuneration to be paid to the auditor.

At the Meeting, shareholders approved the alteration to the Company's share structure to eliminate the Multiple Voting Shares of the Company and re-designate the Subordinate Voting Shares as Common Shares of the Company.

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

For Media: This email address is being protected from spambots. You need JavaScript enabled to view it.
For Investors: This email address is being protected from spambots. You need JavaScript enabled to view it.